Caravan Biologix

Executive Summary

Caravan Biologix is a preclinical-stage cell and gene therapy company developing CAR-Directed BioSpheres (Mini-CAR), an innovative platform designed to overcome key limitations of conventional CAR-T cell therapies. The BioSpheres are derived from allogeneic cells and engineered to display chimeric antigen receptors (CARs) along with optional checkpoint inhibition tags, enabling targeted delivery of apoptotic proteins to diseased cells. This approach aims to emulate the functions of T cells, Natural Killer cells, or macrophages while offering improved safety, scalability, and off-the-shelf availability. Based in San Diego, CA, the company was founded in 2021 and is privately held with no disclosed funding or valuation data. The Mini-CAR technology holds promise for treating a variety of cancers and other diseases by providing a standardized, allogeneic product that reduces manufacturing complexity and patient-specific variability. However, as a preclinical entity, Caravan Biologix faces significant development and regulatory hurdles. The company has not yet reported in vivo efficacy data or advanced toward the clinic. Near-term success depends on securing financing and demonstrating platform proof-of-concept in relevant animal models. Given the early stage and lack of public data, conviction in the platform remains moderate, pending experimental validation.

Upcoming Catalysts (preview)

• Q3 2026First preclinical proof-of-concept data (in vivo efficacy)40% success
• Q4 2026Series A financing round50% success
• 2027Strategic partnership or licensing deal30% success